Safety and tolerability of pur1800, an orally inhaled narrow spectrum kinase inhibitor, in patients with stable chronic obstructive pulmonary disease (copd).

This study evaluated the safety, tolerability and pharmacokinetics of inhaled doses of PUR1800 for 14 days in patients with stable and 1+ y ears of Grade II/III COPD.

Source: Journal of Allergy and Clinical Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Margaret Wasilewski, Russell Clayton, Dave Singh, Jason Perry, Aidan Curran Source Type: research